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2Abstract
Creatine is synthesized from arginine by L-arginine:glycine amidinotransferase (AGAT) and S-
adenosyl-L-methionine:N-guanidinoacetate methyltransferase (GAMT) and can be taken up
by cells by creatine transporters (CRT). While creatine is mainly synthesized by the liver and
the kidney, most of other tissues, including the brain, also express AGAT and GAMT. There
is evidence that the permeability of the blood-brain barrier (BBB) for creatine is limited,
suggesting that the brain is dependent on its own creatine synthesis. In order to better
understand creatine synthesis and transport in the central nervous system (CNS), we studied
the regional distribution of cells expressing AGAT, GAMT and the creatine transporter CRT1
in the adult rat brain by non-radioisotopic in situ hybridization. AGAT and GAMT presented
an ubiquitous neuronal and glial expression, whereas CRT1 was present in neurons and
oligodendrocytes throughout the brain, but not in astrocytes. This indicates that all cells in the
CNS can synthesize creatine from arginine. The absence of expression of CRT1 in astrocytes
and particularly in those contacting capillary endothelial cells (BBB) reinforces the idea that
under normal conditions the creatine used by the brain is synthesized mainly in the CNS.
Furthermore, the expression of CRT1 by neurons and oligodendrocytes indicates that creatine
trafficking is possible in those brain areas of main creatine consumption.
Keywords: brain, creatine, L-Arginine:glycine amidinotransferase, S-Adenosyl-L-
methionine:N-guanidinoacetate methyltransferase, creatine transporter, in situ hybridization.
Theme B: Cellular and Molecular Biology.
Topic: Gene structure and function: general.
31. Introduction
The creatine (Cr)/phosphocreatine (PCr) system is essential for the buffering and transport of
high energy phosphates. In mammals, Cr is synthesized mostly in liver and kidney,
transported through the blood and taken up in tissues with high energy demand by specific Cr
transporters. However, the brain might primarily be dependent on its own Cr synthesis, as
evidence has been presented that the permeability of the blood-brain barrier (BBB) for Cr is
limited (see [41] for a review).
Cr is synthesized by a two-step mechanism involving L-arginine:glycine amidinotransferase
(AGAT; EC 2.1.4.1) and S-adenosyl-L-methionine:N-guanidinoacetate methyltransferase
(GAMT ; EC 2.1.1.2) (see details in Fig. 1). AGAT has been cloned in rat, pig and human
[8,13], and GAMT cDNAs were isolated from rat, mouse and human [14,16,22]. The brain as
well as primary astrocytes in culture are able to synthesize their own creatine [24,35].
Eventhough AGAT activity was detected in the brain [24,35,36], there has been no data on
the expression and localization of the AGAT mRNA or protein. The GAMT activity has
been shown in the brain [36] and characterized in a mouse neuroblastoma cell line [3]. Its
mRNA is expressed in the rat brain [18], but its distribution in the various cell types of the
CNS is not known.
Cr is taken up by cells by specific transporters belonging to the Na+-dependent
neurotransmitter transporter family (see [41] for a review), that have been characterized in rat
[19,26], rabbit [7] and human [15,21,28]. By in situ hybridization (ISH), it has been shown
that the rat Cr transporter CRT1 is highly expressed in the developing CNS of the embryo as
4well as in the adult CNS [9,25,26]. Specifically, the CRT1 mRNA is widely expressed in the
adult brain, in both neuronal and non-neuronal cells, with high levels in the myelinated tracts,
cerebellar granule cells, hippocampal pyramidal cells, several brainstem nuclei and the choroid
plexus. In brain derived cultured cells, the creatine uptake activity has been described in a
mouse neuroblastoma cell line and in both mouse and rat astroglial cultured cells, but not in
neuron enriched cultures, leading to the hypothesis that Cr transport might be an astroglial
rather than a neuronal function [20].
Substantial evidence supports the function of the Cr/PCr system in brain energetic
metabolism. Patients with GAMT deficiency, a recently described autosomal recessive inborn
error of Cr synthesis [6,27,31-34], manifest neurological symptoms in early infancy and show
a severe neurodevelopmental delay as well as extrapyramidal symptoms. Some of these
symptoms are partially reversed with high doses of oral Cr supplementation [6,31].
While these facts support the prominent physiological role of Cr synthesis in CNS, data on
the localization and expression of AGAT and GAMT are lacking. The aim of the present
study was to examine in detail the mRNA expression of the AGAT and GAMT genes in the
brain using non-radioisotopic in situ hybridization. In order to discriminate between transport
and synthesis of Cr, we also investigated the expression of the Cr transporter CRT1. Our
work uses a new combination of in situ hybridization with immunohistochemistry to precisely
identify the cells expressing AGAT, GAMT and CRT1.
52. Materials and Methods
Cloning of CRT1, AGAT and GAMT cDNAs and synthesis of the riboprobes:
Partial cDNAs of the rat sequence CRT1 corresponding to nucleotides 901-2544 (Gene Bank
accession number X66494), of AGAT (nucleotides 182-1314, Gene Bank U07971), and of
GAMT (nucleotides 131-734, Gene Bank J03588) were isolated by reverse transcription-
polymerase chain reaction (Titan One Tube RT-PCR, Roche Molecular Biochemicals, Basel,
Switzerland) using rat kidney mRNA as template. Sequences were verified by sequencing and
inserted into the EcoRI and HindIII multiple cloning sites of pBluescript II KS- (Stratagene)
using the di-/trinucleotide sticky end cloning method [4], yielding pBS-CRT1, pBS-AGAT
and pBS-GAMT. Digoxigenin labelled CRT1, AGAT and GAMT riboprobes were
transcribed in vitro as described previously [1,2]. The antisense probes were transcribed from
the plasmids linearized with XhoI (pBS-CRT1) or XbaI (pBS-AGAT and pBS-GAMT),
while the sense probes were synthesized from the same plasmids linearized with BamHI
(pBS-CRT1), SalI (pBS-AGAT), or XhoI (pBS-GAMT).
In situ hybridization (ISH) and immunohistochemistry
Four female adult Wistar rats (300 g, BRL, Basel, Switzerland) were deeply anesthetized (10
mg/rat Ketalar, Parke Davis, USA) and sacrificed by decapitation. Their brain was extracted
within 2 minutes, immediately embedded in tissue freezing medium (Jung, Nussloch,
Germany) and frozen in isopentane and dry ice. Brains were kept at -80 °C until used, then
cut and analyzed by ISH as described [1,2]. Briefly, cryosections (20 µm thick) were
postfixed 10 min in 4% paraformaldehyde-PBS, washed 2x15 min in PBS containing 0.1%
6fresh DEPC and equilibrated 15 min in 5xSSC. Sections were hybridized (58°C for 40 h in
5xSSC, 50% formamide and 40 µg/ml salmon sperm DNA) with the digoxigenin-labelled
antisense and sense riboprobes (400 ng/ml) for rat CRT1, AGAT and GAMT. The sections
were then washed (30 min in 2xSSC at room temperature, 1 h in 2xSSC at 65°C, 1 h in
0.1xSSC at 65°C) and stained with alkaline-phosphatase (15 h at room temperature). After
staining, the sections were dehydrated and mounted (Eukitt, O.Kindler Gmbh & Co., Freiburg,
Germany). The specificity of hybridization was ascertained by the use of sense probes for
CRT1, AGAT and GAMT genes that have the same length, GC content and activity of
digoxigenin labelling as the corresponding antisense probes. In each ISH experiment, a section
hybridized with a specific antisense probe was always preceded or followed by an adjacent
section hybridized with the corresponding sense control probe.
In each ISH experiment, 3 out of 4 of the antisense ISH stained sections were further
processed for immunohistochemistry. On these sections, neurons, astrocytes and
oligodendrocytes were labelled using monoclonal antibodies directed against Microtubule
Associated Protein 2 (MAP2), Glial Fibrillary Acidic Protein (GFAP) and Myelin Basic
Protein (MBP) (Roche Molecular Biochemicals, Basel, Switzerland) (Boehringer Ingelheim,
Germany), respectively. After rehydration, the ISH stained sections were fixed 1 h in 4%
paraformaldehyde-PBS at room temperature and washed 3x 5min in PBS. After membrane
permeabilization for 5 min in 0.1% sodium citrate and 0.1% Triton X-100, sections were
processed for immunohistochemistry using the Histostain-Plus kit (Zymed Laboratories). The
primary antibody was diluted 1:100 in blocking solution (non-immune serum), and applied for
one hour at room temperature on the sections. After washing away the primary antibody,
7sections were incubated with an anti-mouse IgG biotinylated secondary antibody followed by
a streptavidin-peroxidase conjugate. Peroxidase staining was performed for 10 min using
aminoethyl carbazole (AEC) and H2O2. The double stained sections (blue signal for ISH and
red signal for immunohistochemistry) were mounted in glycerol. The very low level of GAMT
transcript in some areas of the brain, especially the neocortex and the white matter structures
(see Fig. 2g,h and 3i), rendered the detection of GAMT mRNA in the presence of the
immunohistochemical signal difficult. In those cases, the cell identification for GAMT
expression was realized on adjacent sections labelled by immunohistochemistry.
Histological analysis
Sections were observed and photographed on an Olympus BX50 microscope equipped with a
DP-10 digital camera (Olympus Opticals, Japan). No discrepancies was observed between the
four female rats analyzed. Brain structures were identified according to Paxinos and Watson
[23].
83. Results
A semi-quantitative description of AGAT, GAMT and CRT1 mRNA levels in the different
brain structures is given in Table 1. The specificity of hybridization was ascertained in each
case by the absence of signal obtained with the respective sense probes (Fig. 2e,j,o).
L-Arginine:glycine amidinotransferase (AGAT)
The AGAT mRNA was found in neurons, astrocytes and oligodendrocytes throughout the
brain, and its cellular localization was perinuclear. Importantly, the AGAT transcript was
found in the astrocytes contacting capillary and blood vessel endothelium (BBB), as shown by
a co-labelling with GFAP (Fig. 2a, arrow). In the telencephalon, AGAT was expressed
throughout the neocortex, in pyramidal and non-pyramidal neurons as well as in astrocytes,
but for the latter at a much lower level (Fig. 2b). In the corpus callosum, AGAT was located in
astrocytes (Fig. 2c, arrow) and oligodendrocytes (Fig. 2c, asterisk) as demonstrated by the co-
labelling with GFAP and MPB respectively (Fig. 2c and data not shown). AGAT mRNA was
also located in the putamen, globus pallidum, nucleus accumbens, pyriform cortex and its
transition towards the amygdala nuclei, and was abundantly expressed in the olfactory bulb. In
hippocampus, the AGAT transcript was localized at high levels in the CA1 layer and the
dentate gyrus (Fig.2d, DG). The CA3, polymorphic and molecular layers presented a lower
signal, including in the astrocytes (Fig.2d, arrow). Most structures of the diencephalon,
midbrain, pons and medulla showed the AGAT transcript, with higher levels in the reticular
nucleus of thalamus, the posterior lobe of pituitary, the superior colliculus, the red nucleus
and the trapezoid body nucleus, the subcoeruleus, the nucleus of the solitary tract and the
9hypoglossal nucleus. In cerebellar cortex, AGAT was abundantly expressed in neurons of the
granular layer (Fig 3a-c, G). Purkinje cells (Fig. 3b-c, arrowhead) and Bergmann glia (Fig. 3c,
open arrowhead) were positive for AGAT mRNA, but at a very low level of detection, as
shown by a co-labelling with MAP2 and GFAP respectively. AGAT was also found in
neurons of the molecular layer (Fig. 3c), as well as in the deep nuclei of the cerebellum. The
AGAT mRNA was expressed in white matter structures of cerebellum, in cells identified as
astrocytes (Fig.3d-e, arrows) and oligodendrocytes (Fig. 3d-e, asterisks) with a co-labelling by
GFAP and MPB (Fig. 3d and 3e respectively). The AGAT transcript was also revealed in the
choroid plexus and the ependymal epithelium (data not shown).
S-Adenosyl-L-methionine:N-guanidinoacetate methyltransferase (GAMT)
The GAMT mRNA was detected in neurons and glial cells throughout the brain, with
particularly low levels in astrocytes. Its main cellular localization was perinuclear. However, a
lower and diffuse mRNA expression in the cell processes was also observed for GAMT in the
whole brain, particularly in dense fiber regions like the cortex of telencephalon (Fig. 2g). As for
AGAT, the GAMT transcript was found in the astrocytes contacting capillary and blood
vessel endothelia (Fig. 2f, arrow). In the telencephalon, GAMT was expressed at low levels in
neurons and astrocytes of the neocortex (Fig. 2g) as well as in astrocytes (Fig. 2h, arrow) and
oligodendrocytes (Fig. 2h, asterisks) of the corpus callosum. Most other parts of the
telencephalon expressed GAMT, except for the anterior commissure. In the hippocampus, the
GAMT transcript was localized at low to medium levels in the CA1-3 layers, whereas the
dentate gyrus presented higher levels (Fig.2i). Low levels of the GAMT mRNA were found in
most nuclei of the diencephalon, midbrain, pons and medulla. Higher levels were detected in
10
the nucleus of the solitary tract and the hypoglossal nucleus. In cerebellar cortex, GAMT was
expressed in neurons of the granular layer (Fig 3f-h). Purkinje cells (Fig. 3g-h, arrowheads) and
Bergmann glia (Fig. 3h, open arrowhead) were positive for GAMT at a very low level of
detection, as shown by a co-labelling with MAP2 and GFAP respectively. Low levels were
found in the molecular layer and in the deep nuclei of cerebellum. The GAMT mRNA was
expressed in astrocytes (Fig. 3i-j, arrow) and oligodendrocytes (Fig. 3i-j, asterisks, co-labelling
with MBP) of the white matter of the cerebellum. The GAMT transcript was detected at very
low levels in the choroid plexus and the ependymal epithelium (data not shown).
Creatine transporter (CRT1)
Throughout the brain, the CRT1 mRNA was localized in neurons and oligodendrocytes, with
a perinuclear cellular localization. However, as for GAMT, it was also observed as a diffuse
signal in the cell processes throughout the brain, in dense fiber regions like the neocortex. It
was never detected in astrocytes, including those contacting capillary and blood vessel
endothelial cells (BBB), as illustrated with a co-labelling with GFAP (Fig. 2k, arrows). In the
telencephalon, CRT1 was expressed in the neocortex, in pyramidal and non-pyramidal
neurons (Fig. 2l, co-labelling with MAP2). In the corpus callosum, it was located in
oligodendrocytes (Fig. 2m, asterisk) but not in astrocytes (Fig. 2m, arrows) as demonstrated
with a co-labelling by GFAP and MPB (Fig. 2m and data not shown, respectively). CRT1
mRNA was located in the putamen, globus pallidum, nucleus accumbens, pyriform cortex and
in the amygdala nuclei, and presented a higher level in the olfactory bulb. In the hippocampus,
the CRT1 transcript was most abundant in the CA1 layer and the dentate gyrus (Fig.2n).
Most structures of the diencephalon, midbrain, pons and medulla showed the CRT1
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transcript, with higher levels in the posterior lobe of the pituitary, the trapezoid body and
gigantocellular reticulate nuclei, the nucleus of the solitary tract and the hypoglossal nucleus.
In cerebellar cortex, CRT1 was abundantly expressed in neurons of the granular layer (Fig 3k-
m). Purkinje cells were positive for CRT1 mRNA with a very low level of detection (Fig. 3l-
m, arrowhead), but CRT1 could not be detected in the Bergmann glia (Fig. 3m, open
arrowheads). CRT1 was also found in neurons of the molecular layer and in the deep nuclei of
the cerebellum. In the white matter structures of the cerebellum, the CRT1 mRNA could not
be detected in astrocytes (Fig. 3n-o, arrows) but was expressed in oligodendrocytes (Fig. 3n-o,
asterisks), as shown by the co-labelling with GFAP (Fig. 3n) and MBP (Fig. 3o) respectively.
The CRT1 transcript was expressed in the choroid plexus and the ependymal epithelium (data
not shown).
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4. Discussion
4.1: Expression of AGAT, GAMT and CRT1
Although the enzymatic activity of AGAT has been detected in the brain [24,35], no data
were published concerning its cellular expression. In this study, we have shown the ubiquitous
expression of AGAT mRNA in the adult rat brain, namely in neurons, astrocytes and
oligodendrocytes (see summary in Table 2), as well as in the ependymal epithelium and the
choroid plexus. The enzymatic GAMT activity and mRNA were previously reported in the
brain [18,36], but no specific cell type localization has been described so far. Our study
indicates that GAMT is ubiquitously expressed in the adult rat brain, in the same cells as
AGAT but at a lower transcript level. Our work suggests that every cell in the CNS appears
to be able to convert L-arginine to Cr.
The CRT1 transcript has been localized in specific areas of the brain by several authors
[9,25,26]. Our work is in agreement with these studies, showing expression throughout the
brain in both neuronal and non-neuronal cells, with prominent hybridization signals in the
neocortex, white matter structures, granule neurons of dentate gyrus and cerebellum, several
brainstem nuclei and the choroid plexus. Interestingly, and due to our double-labelling
experiments that allowed the identification of the CRT1 expressing cells, we were unable to
localize CRT1 in astrocytes. This result is in contrast with previous data showing the CRT1
activity in astroglial cultures [20]. This could eather mean that astrocytes of the adult rat brain
do not express CRT1 mRNA, or that its expression is below the limit of ISH detection, that
has been estimated at 20-30 transcripts per cell with this probe length (1644 nucleotides, [2]).
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In contrast, CRT1 was well expressed in oligodendrocytes, confirming its expression in the
white matter described earlier [9,25]. The absence of CRT1 mRNA in astrocytes and
particularly in those participating to the BBB suggests that in normal conditions the
production of Cr within the brain is predominant as compared to its blood supply. In a model
of brain cell aggregate cultures issued from the rat embryo neocortex [12], we have also
observed that astrocytes do not express CRT1, contrary to neurons and oligodendrocytes
(manuscript in preparation), confirming the in vivo expression of CRT1 in the brain. The
discrepancy in CRT1 expression between in vivo (this study and [9,25,26]) and culture [20]
conditions suggests that the normal expression of CRT1 in vivo depends on intercellular
interactions.
We have shown that AGAT, GAMT and CRT1 mRNAs are localized or concentrated in the
perinuclear region of the brain cells. However, we have also observed the presence of GAMT
and CRT1 transcripts in the cell processes, as it was observed for CAT3 or nNOS mRNAs
[1]. Thus, GAMT and CRT1 mRNAs might be transported along the cell processes, in order
to allow the brain cells to translate these proteins at the site they are needed. This would allow
the cell to respond rapidly to immediate peripheral needs in Cr, a process of primary
importance during synaptogenesis or growth cone migration which has been shown to be
coupled directly to creatine kinase (CK) or arginine kinase [39]. The anterograde transport of
newly translated proteins towards cell processes is however not excluded for GAMT, CRT1
and AGAT particularly, since its transcript was shown here to be restricted to the perinuclear
region.
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4.2 : Creatine synthesis and transport
The total level of Cr (Cr + PCr) in the CNS seems to correlate well with the brain CK activity
as well as with the expression of the Cr transporter (see [41] and references therein). In
chicken and rat brains, the different isoforms of CK (Brain-CK, Muscle-CK and
Mitochondrial-CK) have been attributed to specific cell types presenting high and fluctuating
energy demands, particularly Bergman glial cells, Purkinje neurons and the glomerular
structures of the cerebellum [10,17,37]. We have shown that AGAT, GAMT and CRT1 are
expressed in these cells, with the exception of CRT1 in the Bergman glia. Important levels of
PCr and total Cr have been described in the white matter structure of human and rat [38,40], in
good correlation with our data on the expression of AGAT, GAMT and CRT1 in
oligodendrocytes. Higher amounts of CK and PCr have been found in glial cells compared to
neurons [10,11] and primary astrocytes are able to synthesize their own Cr [5]. Our work
suggests thus that astrocytes may actually not only cover their own needs in Cr but also
supply some but not all of the Cr needed by other cells, e.g. neurons and oligodendrocytes.
The absence of CRT1 transporter in the astrocytes participating to BBB as well as the
ubiquitous expression of AGAT and GAMT suggest that under normal conditions, the brain
cells synthesizing Cr depend on the uptake of arginine from the blood and on its local
trafficking between the different cell types. Among the different cationic amino acid
transporters (CAT, system y+) responsible for the arginine transport, CAT1 has been shown
at the BBB as well as expressed ubiquitously in neuronal and glial cells of the adult rat brain,
whereas CAT3 was shown restricted to neurons [1,30]. Another form of CAT, CAT2(B),
could be responsible for the arginine trafficking in glial cells [29]. In summary, every brain cell
would be equipped with arginine transporters and would be able to ensure its local needs in
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arginine for Cr synthesis.
In patients with the recently described GAMT deficiency, a marked increase of
guanidinoacetate in the brain, CSF, serum and the urine has been shown with a concomittant
decrease of Cr and PCr in the brain as measured by magnetic resonance spectrometry [6,27,31-
34]. Oral supplementation with Cr (4-8 g_day-1 or 2 g_kg-1_day-1) normalized the brain Cr
concentration very slowly (50% of the normal level after 6 weeks, and the normal level was
reached only after 25 months of treatment; [6,27,31,32]). This observation is in accordance
with our data in the rat and supports the view that in vivo the permeability of the BBB for Cr
is very limited, probably due to the absence of CRT1 expression in the astrocytes
participating to the BBB.
Our data suggest that all cells in the CNS are able to synthesize their own Cr locally because
of their expression of AGAT and GAMT. Moreover, neurons and oligodendrocytes seem able
to take up Cr by expressing CRT1, whereas astrocytes, particularly those contacting the
capillary endothelial cells (BBB), do not express CRT1. This suggests that in normal
conditions Cr for the brain is mainly synthesized there. The brain could therefore be
considered as a near-independent compartment for the synthesis and the use of creatine.
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Figure legends:
Figure 1: Creatine synthesis and uptake. Adomet: S-Adenosyl-L-methionine, AdoHCys:
S-Adenosyl-L-homocysteine, ADP: adenosine diphosphate, AGAT: L-Arginine:glycine
amidinotransferase, Arg: arginine, ATP: adenosine triphosphate, CAT: cationic amino acid
transporter, CK: creatine kinase, CRT1: creatine transporter, GAMT: S-Adenosyl-L-
methionine:N-guanidinoacetate methyltransferase, Gly: glycine, Orn: ornithine.
Figure 2: Expression of AGAT, GAMT and CRT1 mRNA in the telencephalon. a-d: ISH
antisense staining for AGAT, co-labelled by immunohistochemistry for GFAP (a,c,d) and
MAP2 (b). e: ISH sense staining for AGAT. f-i: ISH antisense staining for GAMT, co-
labelled by immunohistochemistry for GFAP (f). j: ISH sense staining for GAMT. k-n: ISH
antisense staining for CRT1, co-labelled by immunohistochemistry for GFAP (k,m) and
MAP2 (l). o: ISH sense staining for CRT1. a,f,k: Blood-brain barrier with astrocytes
(arrows) extending their podocytes towards capillaries. b,g,l: Layer V of neocortex (pyramidal
neurons: arrowheads; diffuse expression of GAMT in cell processes: g, open arrowhead).
c,h,m: White matter of corpus callosum (astrocytes: arrows; oligodendrocytes: asterisks).
d,e,i,j,n,o: Dendate gyrus (DG) and hilus (H) of hippocampus. Bar: 50 µm.
Figure 3: Expression of AGAT, GAMT and CRT1 mRNA in the cerebellum. a-e: ISH
antisense staining for AGAT, co-labelled by immunohistochemistry for MAP2 (b), GFAP
(c,d) and MBP (e). f-j: ISH antisense staining for GAMT, co-labelled by
immunohistochemistry for MAP2 (g), GFAP (h) and MBP (j). k-o: ISH antisense staining
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for CRT1, co-labelled by immunohistochemistry for MAP2 (l), GFAP (m,n) and MBP (o).
a-c, f-h, k-m: Cerebellar cortex. b,c,g,h,l and m are higher magnifications of area 1 examplified
in panel a , showing the granule cell layer (G), the molecular layer (M), the Purkinje cells
(arrowheads) and the Bergmann glia cells (open arrowheads). d,e,i,j, n and o: White matter
of cerebellum with higher magnification of area 2 examplified in panel a  (astrocytes: arrows ;
oligodendrocytes: asterisks). Bar: 100 µm (a,f,k) and 50 µm (b-e, g-j, l-o).
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Table 1: Differential expression of GAT, GAMT and CRT1 in the adult rat brain.
GAT GAMT CRT1
Telencephalon
  Neocortex
    Pyramids of layers III and V + – ++
    Other neurons ++ + ++
    Astrocytes – – -
  Corpus callosum
    Astrocytes + + -
    Oligodendrocytes ++ + ++
  Olfactory bulb +++ + ++
  Anterior olfactory nucleus + + +
  Anterior commissure + - +
  Caudate-Putamen + – +
  Amygdala ++ – +
  Island of Calleja +++ + +
  Nucleus accumbens ++ + +
  Pyriform cortex + + ++
  Hippocampus
    CA1 ++ + ++
    CA3 – – +
    Dentate gyrus +++ ++ +++
    Polymorph./Mol. layers
      Neurons + – +
      Astrocytes + – -
  Septal nuclei ++ – ++
  Diagonal band ++ – ++
  Globus Pallidum ++ + +
Diencephalon
  Thalamus
    Stria medullaris ++ + +
    Laterodorsal nucleus + – +
    Lateroposterior nucleus + – +
    Lateroventral nucleus + – +
    Ventromedial nucleus + – +
    Posterior group nuclei + – +
    Anterior pretectal nucleus + – +
    Reticular nucleus ++ + +
  Hypothalamus
    Lateral hypothalamic area + – +
    Premammillary ventral nucleus + – +
    Zona Incerta + – +
  Preoptic area + – +
  Pituitary (posterior lobe) ++ + ++
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Midbrain
  Superior colliculus ++ + +
  Inferior colliculus + + ±
  Red nucleus ++ + +
  Substantia nigra + ± +
  Retrorubral fields + ± +
Brainstem
  Pontine nucleus + + +
  Trapezoid body nucleus ++ + ++
  Vestibular nuclei + ± +
  Tegmental nuclei ++ + +
  Locus coeruleus + ± +
  Subcoeruleus nuclei ++ ± +
  Reticulate formation + + +
    Gigantocellular reticulate nuclei + + ++
  Inferior olive + + +
  Trigeminal nuclei + + +
  Solitary tract nucleus ++ ++ ++
  Hypoglossal nucleus ++ ++ ++
Cerebellum
  Molecular Layer + + +
  Purkinje cells ± ± ±
  Bergmann glia ± ± -
  Granular layer
    Granule cells ++++ ++ +++
    Astrocytes ± ± -
  Cerebellar white matter
    Astrocytes + ± -
    Oligodendrocytes + ± +
  Deep nuclei neurons ++ ± ++
Choroidal plexus + ± +
Ependymal and subependymal layers ± ± +
-: absent; ±: barely detectable; +: weak expression; ++: moderate expression; +++: strong
expression; ++++: very strong expression. The semi-quantitative description of AGAT,
GAMT and CRT1 mRNA levels is based on ISH only experiments. Levels of transcripts
observed by optical microscopy are indicated by - and + signs, which do not represent a strict
linear measure of mRNA levels.
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Table 2: Summary of GAT, GAMT and CRT1 expression in the rat brain.
GAT GAMT CRT1
Neurons + + +
Astrocytes + + -
Oligodendrocytes + + +
CreatineArg
Arg
CAT
Orn
GAMT
Guanidinoacetate
Creatine
CRT1
AGAT
Gly
AdoMet
AdoHCys
CK
Phosphocreatine
ATP
ADP
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